References
- Barrett JF. Moxifloxacin Bayer. Curr Opin Investig Drugs 2000; 1: 45–51.
- Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J 2000; 76: 479–83.
- Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003; 22: 203–21.
- Eliopoulos GM. In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs 1995;49 Suppl 2: 48–57.
- Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81.
- Johnson AP, Warner M, Livermore DM. Activity of moxifloxacin and other quinolones against pneumococci resis-tant to first-line agents, or with high-level ciprofloxacin resis-tance. Int J Antimicrob Agents 2001; 17: 377–81.
- Lentino JR. Prosthetic joint infections: bane of orthope-dists, challenge for infectious disease specialists. Clin Infect Dis 2003; 36: 1157–61.
- Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369–79.
- Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336: 999–1007.
- Lew DP, Waldvogel FA. Use of quinolones in osteomyelitis and infected orthopaedic prosthesis. Drugs 1999;58 Suppl 2: 85–91.
- Mader JT, Shirtliff M, Calhoun JH. Staging and staging application in osteomyelitis. Clin Infect Dis 1997; 25: 1303–9.
- Malincarne L, Ghebregzabher M, Moretti MV, et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 2006; 57: 950–4.
- Metallidis S, Charokopos N, Nikolaidis J, et al. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery. Int J Antimicrob Agents 2006; 28: 428–32.
- Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tis-sue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35: 1953–9.
- Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tis-sue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother 1991; 35: 1947–52.
- Norden CW. Antibiotic prophylaxis in orthopedic surgery. Rev Infect Dis 1991;13 Suppl 10: S842–6.
- Perez-Trallero E, Garcia-Rey C, Martin-Sanchez AM, et al. Activities of six different quinolones against clinical respira-tory isolates of Streptococcus pneumoniae with reduced sus-ceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 2002; 46: 2665–7.
- Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Jama 1998; 279: 125–9.
- Rimmele T, BoseIli E, Breilh D, et al. Diffusion of lev-ofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004; 53: 533–5.
- von Baum H, Bottcher S, Abel R, et al. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001; 18: 335–40.
- Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998; 20: 1049–70.